Key points are not available for this paper at this time.
A 5‐week trial has found that the combination of the muscarinic receptor agonist xanomeline and the peripheral muscarinic antagonist trospium significantly reduced symptoms of schizophrenia in adults. The xanomeline‐trospium combination was well‐tolerated, with no significant difference from placebo in extrapyramidal symptoms or weight gain.
A Thu, study studied this question.